Lunzer R, Delle-Karth G, Zeitlinger M, Prager M, Pracher L
Wien Klin Wochenschr. 2025; 137(Suppl 1):1-33.
PMID: 39912853
PMC: 11802715.
DOI: 10.1007/s00508-024-02490-7.
Shin J, Lee C, Song J
Sci Rep. 2024; 14(1):25630.
PMID: 39463429
PMC: 11514149.
DOI: 10.1038/s41598-024-77272-2.
Bulnes J, Gonzalez L, Velasquez L, Orellana M, Munoz Venturelli P, Martinez G
Front Cardiovasc Med. 2024; 11:1356023.
PMID: 38993522
PMC: 11236697.
DOI: 10.3389/fcvm.2024.1356023.
Wang X, Baskaran L, Chan M, Boisvert W, Hausenloy D
Cond Med. 2024; 6(2):33-41.
PMID: 38800614
PMC: 11126214.
Pan Y, Wu Y, Liu Y, Wang P, Huang H, Jin J
Immunol Res. 2023; 72(2):347-360.
PMID: 38066380
DOI: 10.1007/s12026-023-09439-4.
TAGAP activates Th17 cell differentiation by promoting RhoA and NLRP3 to accelerate rheumatoid arthritis development.
Sun H, Jiang Q, Fan W, Shen X, Wang Z, Wang X
Clin Exp Immunol. 2023; 214(1):26-35.
PMID: 37458218
PMC: 10711349.
DOI: 10.1093/cei/uxad084.
Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial.
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J
BMJ Open. 2023; 13(2):e067910.
PMID: 36828654
PMC: 9971831.
DOI: 10.1136/bmjopen-2022-067910.
Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence.
Cimmino G, Loffredo F, De Rosa G, Cirillo P
Int J Mol Sci. 2023; 24(3).
PMID: 36768804
PMC: 9917272.
DOI: 10.3390/ijms24032483.
Colchicine reduces atherosclerotic plaque vulnerability in rabbits.
Roubille F, Merlet N, Busseuil D, Ferron M, Shi Y, Mihalache-Avram T
Atheroscler Plus. 2023; 45:1-9.
PMID: 36643998
PMC: 9833268.
DOI: 10.1016/j.athplu.2021.08.008.
The Role of Colchicine in Atherosclerosis: From Bench to Bedside.
Gonzalez L, Bulnes J, Orellana M, Munoz Venturelli P, Rodriguez G
Pharmaceutics. 2022; 14(7).
PMID: 35890291
PMC: 9323936.
DOI: 10.3390/pharmaceutics14071395.
Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials.
Lan S, Hsu C, Lai C, Chang S, Lu L, Hung S
Ann Med. 2022; 54(1):1956-1965.
PMID: 35833737
PMC: 9291717.
DOI: 10.1080/07853890.2022.2096919.
Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.
Chen Y, Zhang H, Chen Y, Li M, Luo W, Liu Y
Clin Rheumatol. 2022; 41(6):1873-1887.
PMID: 35138464
DOI: 10.1007/s10067-022-06050-0.
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19.
Tardif J, Cossette M, Guertin M, Bouabdallaoui N, Dube M, Boivin G
Int J Infect Dis. 2022; 116:387-390.
PMID: 35038601
PMC: 8758567.
DOI: 10.1016/j.ijid.2022.01.020.
Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial.
Akrami M, Izadpanah P, Bazrafshan M, Hatamipour U, Nouraein N, Bazrafshan Drissi H
BMC Cardiovasc Disord. 2021; 21(1):583.
PMID: 34876021
PMC: 8650300.
DOI: 10.1186/s12872-021-02393-9.
The Role of Cytokines Produced via the NLRP3 Inflammasome in Mouse Macrophages Stimulated with Dental Calculus in Osteoclastogenesis.
Mae M, Alam M, Yamashita Y, Ozaki Y, Higuchi K, Ziauddin S
Int J Mol Sci. 2021; 22(22).
PMID: 34830316
PMC: 8618367.
DOI: 10.3390/ijms222212434.
Disease-Modifying Anti-rheumatic Drug Prescription Baihu-Guizhi Decoction Attenuates Rheumatoid Arthritis via Suppressing Toll-Like Receptor 4-mediated NLRP3 Inflammasome Activation.
Li W, Mao X, Wang X, Liu Y, Wang K, Li C
Front Pharmacol. 2021; 12:743086.
PMID: 34675809
PMC: 8525175.
DOI: 10.3389/fphar.2021.743086.
Effects of Gentiopicroside on activation of NLRP3 inflammasome in acute gouty arthritis mice induced by MSU.
He M, Hu C, Chen M, Gao Q, Li L, Tian W
J Nat Med. 2021; 76(1):178-187.
PMID: 34586567
PMC: 8732881.
DOI: 10.1007/s11418-021-01571-5.
Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID).
Pascual-Figal D, Roura-Piloto A, Moral-Escudero E, Bernal E, Albendin-Iglesias H, Perez-Martinez M
Int J Gen Med. 2021; 14:5517-5526.
PMID: 34539185
PMC: 8445096.
DOI: 10.2147/IJGM.S329810.
Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial.
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J
Contemp Clin Trials. 2021; 110:106547.
PMID: 34461322
PMC: 8397504.
DOI: 10.1016/j.cct.2021.106547.
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
Tardif J, Bouabdallaoui N, LAllier P, Gaudet D, Shah B, Pillinger M
Lancet Respir Med. 2021; 9(8):924-932.
PMID: 34051877
PMC: 8159193.
DOI: 10.1016/S2213-2600(21)00222-8.
